Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?
Adenis
A
A
Bonneterre
J
J
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000627:therapeutic use*; D014839:Vomiting / Q000517:prevention & control*
D000970:Antineoplastic Agents; D017294:Ondansetron; D003907:Dexamethasone